8-K 1 f8k12215_oxys.htm CURRENT REPORT


Washington, D.C. 20549



Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 2, 2015



OxySure Therapeutics, Inc.

(Exact name of registrant as specified in its charter)



Delaware   000-54137   71-0960725
(State or other jurisdiction
of incorporation or organization)
  (Commission file number)   (IRS Employer
Identification No.)


10880 John W. Elliott Drive, Suite 600
Frisco, TX 75033
(Address of Principal Executive Offices)

(972) 294-6450
(Registrant’s Telephone Number, Including Area Code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐   Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).


ITEM 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Effective November 30, 2015, the Company changed its name from “OxySure Systems, Inc.” to “OxySure Therapeutics, Inc.” (the “Name Change”) by filing a certificate of amendment (“Certificate of Amendment”) to its Articles of Incorporation with the Secretary of State of the State of Delaware. No other amendments were made to the Company’s Articles of Incorporation. The Certificate of Amendment is attached hereto as Exhibit 3.1 and incorporated herein by reference.

ITEM 7.01 Regulation FD Disclosure.

On December 2, 2015, the Company issued a press release announcing the Name Change. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

The information contained in this Item 7.01 of this report is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

3.1Certificate of Amendment, filed November 30, 2015, to the Company’s Articles of Incorporation
99.1Press release, dated December 2, 2015


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  December 2, 2015 OxySure Therapeutics, Inc.  
  By:   /s/ Julian T. Ross  
  Name:   Julian T. Ross  
Title:   Chairman, Chief Executive Officer,
President, and Chief Financial Officer